Medtronic's Cardiac Pipeline Wins Billing Codes as MiniMed Exchange Nears Expiry

Medtronic won 2028 CPT codes and four clearances, but its MiniMed exchange offer closes 9 October 2026 as R&D costs weigh on returns.

Medtronic is asking investors to weigh a pair of clocks running at very different speeds. One is a regulatory calendar that just delivered permanent U.S. reimbursement for two cardiac devices — but only from January 2028. The other is a corporate deadline measured in days: the exchange offer that will carve the diabetes unit MiniMed out of the group closes on 9 October 2026 at midnight New York time, unless the company extends or terminates it.

The offer covers up to 225,361,295 MiniMed shares and is designed to separate at least 80.1 percent of the diabetes business. Management capacity is tied up in the transaction at the same time as the remaining core must prove that its development spending can generate durable returns.

Fresh Clinical Data Lands at AUGS

Scientific results moved back to center stage this week. At the AUGS 2026 specialist congress on Tuesday, Medtronic presented 24-month findings from the exploratory TITAN-2 study of its Altaviva system, and named a national principal investigator for the clinical ENDURANCE trial. The stock took the news in stride, slipping 1.4 percent in the previous session to close at EUR 77.36. On European trading venues the shares were changing hands at EUR 77.78 on the day the Impact Report appeared, a modest 0.8 percent decline.

The Altaviva data build on a reimbursement breakthrough secured roughly a week earlier, when the American Medical Association granted regular Category I CPT billing codes for the procedure as well as for the Symplicity Spyral system. Those codes take effect in January 2028, giving clinicians a long-term planning basis.

Four Clearances and a Breakthrough Tag

Regulatory momentum has been concentrated in the cardiovascular franchise. On 30 September, the drug-coated IN.PACT BTK balloon received breakthrough device designation from the FDA for arterial disease below the knee, with a global randomized pivotal trial of about 400 patients planned to underpin the filing. The same day brought U.S. clearance and CE marking for the Affera Prism-2 mapping software, alongside a CE mark for the PulseSelect ProxBox adapter — a quartet of wins that strengthens the electrophysiology portfolio.

TD Cowen reaffirmed its Buy rating on 30 September with a price target of $110. The bullish case rests on whether these launches can lift margins after the group sheds lower-margin activities; the bear case points to the gap between spending today and cash flow later, since the billing codes only bite from 2028 while the development budget weighs on the balance sheet now. Delays are a live risk — if the 400-patient IN.PACT BTK study runs longer than planned, market entry slips further.

The Numbers Behind the Pipeline

Underpinning all of it is a research budget that Medtronic disclosed in its Impact Report for fiscal 2026, released alongside the clinical news. The company spent $2.9 billion on research and development, reached more than 315 product approvals in key markets, and says it served over 82 million patients worldwide. Against a market capitalization of EUR 98.55 billion, investors are being asked to accept that those approvals will convert into profitable revenue growth rather than a cost trap.

The decisive variable is commercial execution — whether hospital chains and practices adopt the newly cleared devices quickly enough to justify the outlay. Until the MiniMed exchange formally completes, the market's attention stays split between the spinoff mechanics and the question of whether Medtronic can turn its promised focus into hard cash.